Health economics and outcomes methods in risk-based decision-making for blood safety

Transfusion

Volumn 55, Issue 8, 2015, Pages 2039-2047

  Custer, Brian ^a,b   Janssen, Mart P ^c,d  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SANQUIN RESEARCH   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD DONOR; BLOOD SAFETY; BUDGET IMPACT ANALYSIS; CLINICAL EVALUATION; CONSENSUS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; ECONOMIC EVALUATION; HEALTH; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MATHEMATICAL MODEL; OPERATOR; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK BASED DECISION MAKING; RISK MANAGEMENT; SENSITIVITY ANALYSIS; STUDY DESIGN; UNCERTAINTY; ADVERSE EFFECTS; BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; BUDGET; COST; COST BENEFIT ANALYSIS; ECONOMICS; METHODOLOGY; PROCEDURES; QUALITY ADJUSTED LIFE YEAR; STATISTICAL MODEL;

BLOOD SAFETY; BLOOD TRANSFUSION; BLOOD-BORNE PATHOGENS; BUDGETS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION MAKING; HUMANS; MODELS, ECONOMETRIC; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RESEARCH DESIGN; RISK ASSESSMENT;

EID: 84938959820     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13080     Document Type: Review

References (65)

1. Stein J, Besley J, Brook C, et al., Risk-based decision-making for blood safety: preliminary report of a consensus conference. Vox Sang 2011; 101: 277-81.
2. Leach Bennett J, Blajchman MA, Delage G, et al., Proceedings of a consensus conference: Risk-Based Decision Making for Blood Safety. Transfus Med Rev 2011; 25: 267-92.
3. Epstein JS,. Best practices in regulation of blood and blood products. Biologicals 2012; 40: 200-4.
4. Botta MD, Blendon RJ, Benson JM,. Cost-effectiveness decision making and US public opinion. JAMA Intern Med 2014; 174: 141-3.
5. Parkin D, Appleby J, Maynard A,. Economics: the biggest fraud ever perpetrated on the world? Lancet 2013; 382: e11-5.
6. Sox HC,. Resolving the tension between population health and individual health care. JAMA 2013; 310: 1933-4.
7. Borkent-Raven BA, Janssen MP, van der Poel CL, et al., Cost-effectiveness of additional blood screening tests in the Netherlands. Transfusion 2012; 52: 478-88.
8. Custer B, Agapova M, Martinez RH,. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion 2010; 50: 2461-73.
9. Goodell AJ, Bloch EM, Krause PJ, et al., Costs, consequences, and cost-effectiveness of strategies for Babesia microti donor screening of the US blood supply. Transfusion 2014; 54: 2245-57.
10. Janssen MP, van der Poel CL, Buskens E, et al., Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. Transfusion 2006; 46: 956-65.
11. Oei W, Janssen MP, van der Poel CL, et al., Modeling the transmission risk of emerging infectious diseases through blood transfusion. Transfusion 2013; 53: 1421-8.
12. Oei W, Kretzschmar ME, Zaaijer HL, et al., Estimating the transfusion transmission risk of Q fever. Transfusion 2014; 54: 1705-11.
13. Wilson K,. A framework for applying the precautionary principle to transfusion safety. Transfus Med Rev 2011; 25: 177-83.
14. Busch M, Walderhaug M, Custer B, et al., Risk assessment and cost-effectiveness/utility analysis. Biologicals 2009; 37: 78-87.
15. Custer B,. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004; 18: 127-43.
16. Custer B, Hoch JS,. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009; 23: 1-12.
17. Kacker S, Frick KD, Tobian AA,. The costs of transfusion: economic evaluations in transfusion medicine, Part 1. Transfusion 2013; 53: 1383-5.
18. Kacker S, Frick KD, Tobian AA,. Establishing a framework: economic evaluations in transfusion medicine, Part 2. Transfusion 2013; 53: 1634-6.
19. Kacker S, Frick KD, Tobian AA,. Constructing a model: economic evaluations in transfusion medicine, Part 3. Transfusion 2013; 53: 1885-7.
20. Kacker S, Frick KD, Tobian AA,. Data and interpretation: economic evaluations in transfusion medicine, Part 4. Transfusion 2013; 53: 2130-3.
21. van Hulst M, de Wolf JT, Staginnus U, et al., Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002; 83: 146-55.
22. van Hulst M, Smit Sibinga CT, Postma MJ,. Health economics of blood transfusion safety-focus on sub-Saharan Africa. Biologicals 2010; 38: 53-8.
23. Cookson R, McCabe C, Tsuchiya A,. Public healthcare resource allocation and the Rule of Rescue. J Med Ethics 2008; 34: 540-4.
24. Desser AS, Olsen JA, Grepperud S,. Eliciting preferences for prioritizing treatment of rare diseases: the role of opportunity costs and framing effects. Pharmacoeconomics 2013; 31: 1051-61.
25. Gill B, Griffin B, Hesketh B,. Changing expectations concerning life-extending treatment: the relevance of opportunity cost. Soc Sci Med 2013; 85: 66-73.
26. Mauskopf JA, Sullivan SD, Annemans L, et al., Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices-budget impact analysis. Value Health 2007; 10: 336-47.
27. Trueman P, Drummond M, Hutton J,. Developing guidance for budget impact analysis. Pharmacoeconomics 2001; 19: 609-21.
28. Pliskin JS, Shepard DS, Weinstein MC,. The quality-adjusted life year (QALY) is a measure of disease burden, including both the quality and the quantity of life lived. Oper Res 1980; 28: 18.
29. Dolan P,. Utilitarianism and the measurement and aggregation of quality-adjusted life years. Health Care Anal 2001; 9: 65-76.
30. Johannesson M,. Theory and methods of economic evaluation of health care. Dev Health Econ Public Policy 1996; 4: 1-245.
31. Holmes D,. Report triggers quibbles over QALYs, a staple of health metrics. Nat Med 2013; 19: 248.
32. Liljas B,. On the welfare theoretic foundation of cost-effectiveness analysis-the case when survival is not affected. Eur J Health Econ 2010; 11: 5-13.
33. Liljas B, Lindgren B,. On individual preferences and aggregation in economic evaluation in healthcare. Pharmacoeconomics 2001; 19: 323-35.
34. Schlander M,. Measures of efficiency in healthcare: QALMs about QALYs? Z Evid Fortbild Qual Gesundhwes 2010; 104: 214-26.
35. Tufts Medical Center. Cost-Effectiveness Analysis Registry. Boston: Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; c2007-2013 [cited 2014 Nov 4]. Available from: https://research.tufts-nemc.org/cear/
36. World Health Organization. CHOosing Interventions that are Cost Effective (WHO-CHOICE). Geneva: World Health Organization; 2007 [cited 2014 Nov 4]. Available from: http://www.who.int/choice/en/
37. Custer BS,. Good evidence begets good policy: or so it should be. Transfusion 2012; 52: 463-5.
38. Caro JJ, Briggs AH, Siebert U, et al., Modeling good research practices-overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health 2012; 15: 796-803.
39. Roberts M, Russell LB, Paltiel AD, et al., Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Value Health 2012; 15: 804-11.
40. Sonnenberg FA, Beck JR,. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-38.
41. Briggs AH, Sculpher MJ,. An introduction to Markov modelling for economic evaluation. PharmacoEconomics 1998; 13: 397-409.
42. Rossi C, Schwartzman K, Oxlade O, et al., Hepatitis B screening and vaccination strategies for newly arrived adult Canadian immigrants and refugees: a cost-effectiveness analysis. PLoS One 2013; 8: e78548.
43. Eddy DM, Hollingworth W, Caro JJ, et al., Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making 2012; 32: 733-43.
44. Mandelblatt J, Schechter C, Levy D, et al., Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Med Decis Making 2012; 32: 656-9.
45. Neil N,. Transparently, with validation. Med Decis Making 2012; 32: 660-2.
46. Roberts M, Russell LB, Paltiel AD, et al., Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Making 2012; 32: 678-89.
47. Siebert U, Alagoz O, Bayoumi AM, et al., State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making 2012; 32: 690-700.
48. Smith-Spangler CM,. Transparency and reproducible research in modeling: why we need it and how to get there. Med Decis Making 2012; 32: 663-6.
49. Saltelli A, Ratto M, Andres T, et al., Global sensitivity analysis: the primer. New York: Wiley; 2008.
50. Van Asselt MB,. Perspectives on uncertainty and risk: the PRIMA approach to decision support. Dordrecht: Kluwer Academic Publishers; 2000.
51. Walker WE, Harremoës P, Rotmans J, et al., Defining uncertainty: a conceptual basis for uncertainty management in model-based decision support. Integrated Assessment 2003; 4: 5-17.
52. Refsgaard JC, van der Sluijs JP, Højberg AL, et al., Uncertainty in the environmental modelling process-a framework and guidance. Environ Model Software 2007; 22: 1543-56.
53. Brugnach M, Dewulf A, Pahl-Wostl C, et al., Toward a relational concept of uncertainty: about knowing too little, knowing too differently, and accepting not to know. Ecol Soc 2008; 13: 30.
54. Andronis L, Barton P, Bryan S,. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol Assess 2009; 13: 1-61.
55. The precautionary principle: application and way forward. Brussels: European Risk Forum; 2011.
56. Yang H, Gregori L, Asher DA, et al., Draft quantitative risk assessment of vCJD risk potentially associated with the transfusion of red blood cells in the U.S. Silver Spring (MD): Center for Biologics Evaluation and Research, U.S. Food and Drug Administration; 2013.
57. Teljeur C, Flattery M, Harrington P, et al., Cost-effectiveness of prion filtration of red blood cells to reduce the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease in the Republic of Ireland. Transfusion 2012; 52: 2285-93.
58. Tyshenko MG, ElSaadany S, Oraby T, et al., Expert elicitation for the judgment of prion disease risk uncertainties. J Toxicol Environ Health A 2011; 74: 261-85.
59. Tyshenko MG, ElSaadany S, Oraby T, et al., Expert judgement and re-elicitation for prion disease risk uncertainties. Int J Risk Assessment Management 2012; 16: 29.
60. Borkent-Raven BA, Janssen MP, van der Poel CL, et al., The PROTON study: profiles of blood product transfusion recipients in the Netherlands. Vox Sang 2010; 99: 54-64.
61. Borkent-Raven BA, Janssen MP, van der Poel CL, et al., Survival after transfusion in the Netherlands. Vox Sang 2011; 100: 196-203.
62. Goncalez TT, Sabino EC, Capuani L, et al., Blood transfusion utilization and recipient survival at Hospital das Clinicas in Sao Paulo, Brazil. Transfusion 2012; 52: 729-38.
63. Kamper-Jørgensen M, Ahlgren M, Rostgaard K, et al., Survival after blood transfusion. Transfusion 2008; 48: 2577-84.
64. Kleinman S, Marshall D, AuBuchon J, et al., Survival after transfusion as assessed in a large multistate US cohort. Transfusion 2004; 44: 386-90.
65. Menitove JE, Leach Bennett J, Tomasulo P, et al., How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making. Transfusion 2014; 54: 753-7.